Takeda Licenses Anaemia Drug

US-based drugmaker AMAG Pharmaceuticals and Japan's largest pharmaceutical company Takeda have announced a strategic alliance for the licensing, development and commercialisation of Feraheme (ferumoxytol). BMI notes that this collaboration is in line with a general risk-sharing trend. Following the release of the news, shares of AMAG rose 3%, or $1.06 to $36.81 in pre-market

To read the full article, please choose one of the following options: